Vaccinex, Inc. Announces Reverse Stock Split
February 15, 2024 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Op-Ed Submission: Alberta’s Alarming Rise in Dementia
February 06, 2024 15:07 ET
|
Alzheimer Society of Alberta and NWT
Edmonton, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Op-Ed: Alberta’s Alarming Rise in Dementia By Dr. Roger Wong, Member of the Order of Canada, clinical professor in the Division of Geriatric Medicine in...
Global Neurological Biomarkers Market Analysis Report 2024-2030 - CAGR of 12.8% - Increased Funding For R&D in Biomarkers to Boost Development of New Drugs
January 24, 2024 05:40 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism),...
BioVie Sued By Block & Leviton LLP for Securities Law Violations
January 19, 2024 19:18 ET
|
Block & Leviton LLP
BOSTON, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of...
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
January 08, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
January 03, 2024 07:00 ET
|
Athira Pharma, Inc.
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
December 26, 2023 12:45 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX AND MEDSAN CONTRACT TO ADVANCE STUDY INTENDED TO PERSONALIZE MEDICAL EVALUATIONS FOR PATIENTS RECEIVING TREATMENT FOR WET MACULAR DEGENERATION
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board
December 21, 2023 05:50 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS ANATOLY DRITSCHILO, M.D. TO THE COMPANY’S MEDICAL ADVISORY BOARD
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
December 15, 2023 07:22 ET
|
AC Immune SA
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of...
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
December 12, 2023 07:00 ET
|
Athira Pharma, Inc.
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...